Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Accounts Payables: 2009-2024

Historic Accounts Payables for Gyre Therapeutics (GYRE) over the last 15 years, with Dec 2024 value amounting to $108,000.

  • Gyre Therapeutics' Accounts Payables rose 83.50% to $556,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $556,000, marking a year-over-year increase of 83.50%. This contributed to the annual value of $108,000 for FY2024, which is 69.58% down from last year.
  • Gyre Therapeutics' Accounts Payables amounted to $108,000 in FY2024, which was down 69.58% from $355,000 recorded in FY2023.
  • Gyre Therapeutics' Accounts Payables' 5-year high stood at $6.4 million during FY2021, with a 5-year trough of $108,000 in FY2024.
  • Its 3-year average for Accounts Payables is $195,000, with a median of $122,000 in 2022.
  • Per our database at Business Quant, Gyre Therapeutics' Accounts Payables tumbled by 98.10% in 2022 and then skyrocketed by 190.98% in 2023.
  • Yearly analysis of 5 years shows Gyre Therapeutics' Accounts Payables stood at $5.9 million in 2020, then climbed by 8.23% to $6.4 million in 2021, then crashed by 98.10% to $122,000 in 2022, then surged by 190.98% to $355,000 in 2023, then plummeted by 69.58% to $108,000 in 2024.